Advancing Lifelong Vision Health
Visual health is a critical part of well-being
At Vision Labs we believe that vision care is one of the most important aspects of any individual's health care regime and overall well-being. For most, it is a medical aspect that has been neglected due to many factors, and this is what we believe we can change.
Many eye conditions are treatable, if detected early, something we enable in an innovative and cost-effective way, allowing us to make a more proactive approach to vision care and vision health a reality, for everyone.
​
Revolutionizing eye assessments for better visual health
Vision Labs has developed a MOBILE corneal topographer that simplifies the process of establishing a corneal topography of the eye. This is a critical instrument in gathering data and assisting medical professionals evaluating certain eye conditions and actions, including:​
​
-
Dry Eye disease
-
Assessment of Keratoconus, pellucid marginal degeneration and post-refractive surgery ectasia
-
Astigmatism assessment
-
Measurement of Corneal Power
-
​Contact Lense Fitting
​
Vision Labs leverages the latest in mobile technology, cloud computing and emerging technologies to develop additional capability and strive to expand the rich feature set it already provides.
​
​The Vision Labs CLEA device is an innovative medical device, that forms part of the Vison Labs platform. It has an attractive and simple form-factor and brings all the capabilities of far more expensive desktop legacy devices to the palm of your hand. The Vision Labs platform approach allows us to leverage the latest technology advances to expand its feature set in a process of continuous improvement, at a scale not possible before.
Introducing the Vision Labs CLEA Device
Latest News
Vision Labs' CLEA device tested by UCSF Medical Center
Vision Labs and the Paediatric Ophthalmology Department at UCSF Medical Center have collaborated to test the CLEA device with pediatric patients at risk of keratoconus. Dr. Manaasa Indaram, Associate Professor and Medical Director of Paediatric Ophthalmology and Adult Strabismus at University of California San Francisco, led the study and has recently submitted their findings to the American Academy of Ophthalmology (AAO). The CLEA device was effective at identifying corneal abnormalities in a typically difficult to screen population, with mobility and form factor proving highly effective. We continue to collaborate with UCSF in an expanded target population to improve and enhance the capabilities of the Vision Labs platform.
​​
This engagement provided strong validation for the relevance of Vision Labs' CLEA device, with the feedback providing practical input for further improvements and evolution of the overall solution.
UCSF Medical Center, Mission Bay, San Francisco